Table 2.

Univariate and multivariate analysis of progression-free survival and disease-specific survival in advanced stage.

Progression-free survival
Variables	Categories	Univariate analysis		Multivariate analysis
		Progression-free survival		Progression-free survival
		HR (95% CI)	P	HR (95% CI)	P
Age (y)	<65 vs z 65	3.46 (1.01–13.35)	0.05*
Pathologic tumor status	pT1 +pT2 vs pT3 +pT4	2.00 (0.57–7.07)	0.27
Pathologic node status	pN− vs pN+	0.37 (0.05–1.81)	0.23
Pathologic metastasis status	pM0 vs pM1	2.60 (0.39–21.47)	0.32
Clinical stage	1 vs 2 + 3 + 4	1.04 (0.28–4.09)	0.95
Histological grade	1 vs 2	1.59 (0.45–5.65)	0.47
YK criteria	1 +2 vs 3 + 4	8.05 (1.31–156.4)	0.02*
CD163 positive cells	Low vs high	1.53 (0.77 – 3.02)	0.21	1.18 (0.57 – 2.42)	0.64
CD204 positive cells	Low vs high	1.79 (0.92 – 3.52)	0.08	1.77 (0.89 – 3.52)	0.10
CD163+CD204+ cells	Low vs high	2.07 (1.04–4.32)	0.03*	1.97 (0.94 – 4.30)	0.07
Disease-specific survival
Variables	Categories	Univariate analysis		Multivariate analysis
		Disease-specific survival		Disease-specific survival
		HR (95% CI)	P	HR (95% CI)	P
Age (y)	<65 vs z65	1.39 (0.69–2.86)	0.34
Pathologic tumor status	pT1 +pT2 vs pT3 +pT4	1.79 (0.84–3.63)	0.12
Pathologic node status	pN− vs pN+	0.99 (0.39–2.17)	0.98
Pathologic metastasis status	pM0 vs pM1	5.58 (1.17–21.3)	0.03
Clinical stage	1 vs 2 + 3 + 4	1.18 (0.57–2.54)	0.65
Histological grade	1 vs 2	1.20 (0.58–2.41)	0.60
YK criteria	1 +2 vs 3 + 4	1.23 (0.54–3.32)	0.62
CD163 positive cells	Low vs high	1.22 (0.57–2.50)	0.58	1.20 (0.56–2.46)	0.61
CD204 positive cells	Low vs high	1.46 (0.71–2.94)	0.28	1.16 (0.41–4.14)	0.79
CD163+CD204+ cells	Low vs high	1.45 (0.72–2.97)	0.29	1.22 (0.34–3.41)	0.72

HR, hazard ratio; CI, confidence interval, *Significant.